Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T76685 | ||||
| Target Name | Cannabinoid receptor 1 (CB1) | ||||
| Synonyms | Cannabinoid CB1 receptor; CNR; CB-R; CANN6 | ||||
| Target Type | Successful | ||||
| Gene Name | CNR1 | ||||
| Biochemical Class | GPCR rhodopsin | ||||
| UniProt ID | CNR1_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Schizophrenia | ||||
| Example drug | CBD cannabis derivative | Discontinued in Phase 1 | [1], [2], [3] | ||
| Tissue | Pre-frontal cortex | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.22 Z-score: -0.45 P-value: 5.59E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Schizophrenia | ||||
| Example drug | CBD cannabis derivative | Discontinued in Phase 1 | [1], [2], [3] | ||
| Tissue | Superior temporal cortex | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.06 Z-score: -0.46 P-value: 7.68E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Type 2 diabetes | ||||
| Example drug | V-24343 | Phase 1 | [2], [3], [4] | ||
| Tissue | Liver tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 8.39E-05 Z-score: 4.59E-04 P-value: 7.77E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Ovarian cancer | ||||
| Tissue | Ovarian tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.27 Z-score: -0.6 P-value: 1.95E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: -0.2 Z-score: -0.59 P-value: 3.89E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | ClinicalTrials.gov (NCT00734201) Safety and Efficacy of Low Doses of V24343 in Obese Subjects. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.